1. Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing
- Author
-
Aleksander Salomon-Perzyński, Joanna Barankiewicz, Marcin Machnicki, Irena Misiewicz-Krzemińska, Michał Pawlak, Sylwia Radomska, Agnieszka Krzywdzińska, Aleksandra Bluszcz, Piotr Stawiński, Małgorzata Rydzanicz, Natalia Jakacka, Iwona Solarska, Katarzyna Borg, Zofia Spyra-Górny, Tomasz Szpila, Bartosz Puła, Sebastian Grosicki, Tomasz Stokłosa, Rafał Płoski, Ewa Lech-Marańda, Jana Jakubikova, and Krzysztof Jamroziak
- Subjects
clonal evolution ,multiple myeloma ,next-generation sequencing ,Biology (General) ,QH301-705.5 - Abstract
Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four different patterns of mutation evolution were found: branching-, mutation acquisition-, mutation loss- and a stable mutational pathway. Better response to anti-myeloma therapy was more frequently observed in patients who followed the mutation loss—compared to the mutation acquisition pathway. More than two-thirds of patients had druggable genes mutated (including cases of heavily pre-treated disease). Only 7% of patients had a stable copy number variants profile. Consequently, a redistribution in stages according to R-ISS between the first and paired samples (R-ISS″) was seen. The higher the R-ISS″, the higher the risk of MM progression and death. We provided new insights into the genetics of MM evolution, especially in heavily pre-treated patients. Additionally, we confirmed that redefining R-ISS at MM relapse is of high clinical value.
- Published
- 2022
- Full Text
- View/download PDF